Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: What Does It Mean for the Stock?

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASLN : 0.9700 (-3.95%)
ASLAN Pharmaceuticals Ltd. (ASLN) Gains But Lags Market: What You Should Know

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.

ASLN : 0.9700 (-3.95%)
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA

The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.

SNY : 44.83 (+3.03%)
REGN : 493.32 (-1.09%)
ALNY : 105.82 (+1.54%)
ASLN : 0.9700 (-3.95%)
Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year?

Is (ASLN) Outperforming Other Medical Stocks This Year?

ASLN : 0.9700 (-3.95%)
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

ALXN : 89.77 (-0.64%)
CLSN : 0.8868 (-2.55%)
AVXL : 2.62 (-0.38%)
ASLN : 0.9700 (-3.95%)
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

ALXN : 89.77 (-0.64%)
MNTA : 24.19 (-0.29%)
CLSN : 0.8868 (-2.55%)
ASLN : 0.9700 (-3.95%)
Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

RARE : 48.30 (-3.44%)
CLSN : 0.8868 (-2.55%)
ALXN : 89.77 (-0.64%)
ASLN : 0.9700 (-3.95%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ASLN : 0.9700 (-3.95%)
Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?

Is (ASLN) Outperforming Other Medical Stocks This Year?

ASLN : 0.9700 (-3.95%)
Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

ASLN : 0.9700 (-3.95%)
Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor ASLAN Pharmaceuticals.

ASLN : 0.9700 (-3.95%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

BAYRY : 14.3400 (-0.62%)
AVEO : 3.47 (-5.45%)
RARE : 48.30 (-3.44%)
ASLN : 0.9700 (-3.95%)
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ACOR : 0.8700 (+2.96%)
ICPT : 58.75 (-2.38%)
AVEO : 3.47 (-5.45%)
ASLN : 0.9700 (-3.95%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ASLN : 0.9700 (-3.95%)
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASLN : 0.9700 (-3.95%)
Top Ranked Momentum Stocks to Buy for March 29th

Top Ranked Momentum Stocks to Buy for March 29th

SAFM : 106.66 (-2.55%)
ASLN : 0.9700 (-3.95%)
ACIA : 66.40 (-0.63%)
Top Ranked Momentum Stocks to Buy for March 28th

Top Ranked Momentum Stocks to Buy for March 28th

ASLN : 0.9700 (-3.95%)
ANF : 8.06 (+1.13%)
ADXS : 0.5378 (+2.59%)
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

RHHBY : 41.1200 (-1.27%)
ACOR : 0.8700 (+2.96%)
VNDA : 10.27 (-6.81%)
ASLN : 0.9700 (-3.95%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.23 , SEDG -2.49 , THC -1.30 , TER -0.57 , LITE -3.30
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar